1h Free Analyst Time
The cytomegalovirus (CMV) therapeutics market is forecasted to grow by USD 270.4 million during 2023-2028, accelerating at a CAGR of 4.5% during the forecast period. The report on the cytomegalovirus (CMV) therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by growing risk factors for cmv, recurring nature of the disease, and high prevalence of congenital cmv.
The cytomegalovirus (CMV) therapeutics market is segmented as below:
By Route Of Administration
- Oral
- Parenteral
- Others
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the cytomegalovirus (CMV) therapeutics market covers the following areas:
- Cytomegalovirus (CMV) Therapeutics Market sizing
- Cytomegalovirus (CMV) Therapeutics Market forecast
- Cytomegalovirus (CMV) Therapeutics Market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Route of Administration
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Opportunity/Restraints
10 Competitive Landscape
11 Competitive Analysis
12 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global cytomegalovirus (CMV) therapeutics market: Astellas Pharma Inc., AstraZeneca Plc, Bausch Lomb Corp., Chimerix Inc., Clinigen Group Plc, Exela Pharma Sciences LLC, F. Hoffmann La Roche Ltd., Fortress Biotech Inc., Fresenius SE and Co. KGaA, Genentech Inc., Gilead Sciences Inc., Merck and Co. Inc., ProBioGen AG, Synklino AS, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Thermo Fisher Scientific Inc., UbiVac, and VBI Vaccines Inc..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is reformulation of drugs."
According to the report, one of the major drivers for this market is the growing risk factors for cmv.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Astellas Pharma Inc.
- AstraZeneca Plc
- Bausch Lomb Corp.
- Chimerix Inc.
- Clinigen Group Plc
- Exela Pharma Sciences LLC
- F. Hoffmann La Roche Ltd.
- Fortress Biotech Inc.
- Fresenius SE and Co. KGaA
- Genentech Inc.
- Gilead Sciences Inc.
- Merck and Co. Inc.
- ProBioGen AG
- Synklino AS
- Takeda Pharmaceutical Co. Ltd.
- Teva Pharmaceutical Industries Ltd.
- Thermo Fisher Scientific Inc.
- UbiVac
- VBI Vaccines Inc.
